EU Project Explores How To Engage Patient Organizations In Drug Development, Approval
This article was originally published in SRA
Executive Summary
As groups and bodies with an interest in drug development increasingly recognize the benefits of incorporating the views of patients in their decision-making processes, work is under way in the EU to develop guidelines on how patient organizations should interact with the pharmaceutical industry, ethics committees, health technology assessment bodies and regulators.